AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12414411
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3% applied four times daily for 3 days before surgery
Trial: 31791688
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel 80 mg/m2 and carboplatin AUC5 or AUC6 every 3 weeks (Group 2)
Trial: 21880911
Drug: CRF(1) antagonist
RxNorm normalized name: CRF
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRF(1) antagonist GW876008
Trial: 15615349
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of drugs with complementary mechanisms
Trial: 11977649
Drug: Pre-operative intra-arterial
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative intra-arterial infusion chemotherapy (mitomycin 10 mg, 5-FU 1,000 mg, epirubicin 60 mg)
Trial: 2576397
Drug: CV 205‐502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV 205‐502 (0.05 mg daily)
Trial: 2576397
Drug: CV 205‐502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV 205‐502 (mean 0.09 mg a day)
Trial: 795022
Drug: 0.50 g
RxNorm normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 g a day of penicillamine
Trial: 795022
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg a day of zinc metal supplement with 0.50 g a day of penicillamine
Trial: 795022
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg a day of zinc metal supplement with 1 g a day of penicillamine
Trial: 795022
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 0.50 g a day of penicillamine
Trial: 795022
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 1 g a day of penicillamine
Trial: 795022
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with zinc supplement
Trial: 27592680
Drug: Immunoglobulin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (200 mg)
Trial: 27592680
Drug: Combination lactoferrin/immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination lactoferrin/immunoglobulin (200 mg/800 mg)
Trial: 25760977
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles with a fixed 3-month interval after the first four courses)
Trial: 25760977
Drug: Continuous docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles)
Trial: 22268979
Drug: Mindfulness-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based treatment (MBT, n = 12)
Trial: 22268979
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment (CBT, n = 8)
Trial: 18779611
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m(2))
Trial: 8942008
Drug: D'Allergen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D'Allergen treatment
Trial: 6125483
Drug: Tofizopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofizopam (100 mg)
Trial: 6125483
Drug: Tofizopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofizopam (100 mg, three times)
Trial: 25715664
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose X-ray examination (0.365 mSv)
Trial: 8781825
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg t.i.d.) as adjuvant therapy to standard therapy
Trial: 8781825
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (thrombolysis, beta-blockers, and nitrates)
Trial: 1464341
Drug: Captopril (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (both doses)
Trial: 6099135
Drug: Alpha 2-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha 2-adrenoceptor agonist alpha-methylnoradrenaline (MNA)
Trial: 19665770
Drug: Milk oral
RxNorm normalized name: lytes/dextros/mvn/AA/ging/milk ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk oral immunotherapy (MOIT)
Trial: 25362822
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of omega-3
Trial: 25362822
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of omega-3
Trial: 24023786
Drug: simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg
Trial: 2894081
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of flurbiprofen and terfenadine
Trial: 31866308
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg 3 x daily for 10 days)
Trial: 31866308
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 x daily for 10 days)
Trial: 31866308
Drug: Withdrawal (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal (150 mg caffeine 3 x daily for eight days, followed by placebo for two days)
Trial: 23772581
Drug: Medical and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical and rehabilitation treatment (Group 1)
Trial: 23772581
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (Group 2)
Trial: 15525889
Drug: Percutaneous Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous Ethanol Injection (PEI)
Trial: 6255535
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg daily)
Trial: 3664330
Drug: Nystatin (500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin (500,000 units four times daily)
Trial: 22149546
Drug: hsCRP in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP in subjects with NAFLD (4.2±1.2 mg/L)
Trial: 7576895
Drug: Selenium supplemented
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplemented formula (17 micrograms Se/L)
Trial: 7576895
Drug: Unsupplemented formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupplemented formula (4.6 micrograms Se/L)
Trial: 2156764
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon cream (IFN) - 9 x 10(6) IU applied deep into the vagina every night for 2-week courses 1 week apart, for a total treatment period of 12 months.
Trial: 21562449
Drug: Tacrolimus (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (mean level 7.2 ± 2.54 ng/mL)
Trial: 21562449
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) (mean dose 1.5 ± 0.61 g/day)
Trial: 16490760
Drug: Magnesium gluconate
RxNorm normalized name: Magnesium Gluconate
DrugBank: Magnesium gluconate (DB13749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium gluconate (i.v. bolus of 0.21 mmol kg(‐1) followed by a continuous infusion of 0.03 mmol(‐1) kg(‐1) h(‐1))
Trial: 7839784
Drug: 2 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg.kg‐1 of racemic ketamine
Trial: 7839784
Drug: 1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg‐1 of S‐(+) ketamine
Trial: 7839784
Drug: 0.1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg.kg‐1 of midazolam (prior administration)
Trial: 3277779
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg boluses every 6 hours
Trial: 3277779
Drug: Ranitidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine infusion (125 micrograms/kg.h)
Trial: 14633757
Drug: i.v. midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. midazolam sedation (titrated at 0.5 mg x min(‐1), maximum 5 mg)
Trial: 12207629
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler (MDI)
Trial: 6378239
Drug: Cold-adapted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted recombinant virus vaccine (A/Washington/80, H3N2)
Trial: 19254354
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Acotiamide
Trial: 19254354
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Acotiamide
Trial: 16896273
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg and Atorvastatin 10 mg
Trial: 9310278
Drug: Mustard oil
RxNorm normalized name: mustard oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mustard oil (alpha-linolenic acid, 2.9 g/day)
Trial: 28854066
Drug: Dacarbazine (850,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (850, 1,000, or 1,200 mg/m2 intravenously on day 1 every 21 days)
Trial: 16543297
Drug: Training and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training and support intervention delivered to nursing home staff over 10 months, focusing on alternatives to drugs for the management of agitated behaviour in dementia
Trial: 8250308
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine added to general anesthesia
Trial: 30322751
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate (1000 mL bolus)
Trial: 21402860
Drug: 200‐mg rifamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mg rifamycin SV MMX modified‐release tablets
Trial: 18496232
Drug: Prednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1 mg/kg/d)
Trial: 18496232
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg/d)
Trial: 12714403
Drug: Viscocanalostomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscocanalostomy with reticulated hyaluronic acid implant (VSRHAI)
Trial: 21801403
Drug: AMG 108
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 108 (300 mg SC)
Trial: 12828691
Drug: Four double-pass
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four double-pass treatments at 2-week intervals
Trial: 8497683
Drug: ONO‐1078 (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO‐1078 (225 mg twice a day)
Trial: 21459680
Drug: Celecoxib 50
RxNorm normalized name: celecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 50 mg bid
Trial: 22859357
Drug: Celecoxib 800/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 800/400 mg
Trial: 8441139
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg tid
Trial: 15877867
Drug: Carrot juice
RxNorm normalized name: carrot juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot juice (330 ml/d, 27.1 mg beta-carotene, 13.1 mg alpha-carotene) for 2 weeks
Trial: 12929855
Drug: Deltamethrin-treated mosquito
RxNorm normalized name: mosquito allergenic extract
DrugBank: Aedes taeniorhynchus (DB10691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltamethrin-treated mosquito nets, mosquito repellent cream, and weekly chemoprophylaxis with 300 mg chloroquine
Trial: 11405384
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg rofecoxib
Trial: 15309591
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg rofecoxib
Trial: 1486963
Drug: Piretanide (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (24 mg)
Trial: 22216503
Drug: Frusemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (40 mg)
Trial: 24667502
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lectures and dissection-based laparoscopic training (Group III)
Trial: 18843939
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or typical/atypical antipsychotics
Trial: 2658526
Drug: Flosequinan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan (100 mg)
Trial: 27058964
Drug: Stabilization splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilization splint therapy
Trial: 28013329
Drug: Cisatracurium besylate
RxNorm normalized name: Cisatracurium Besylate
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium besylate (NMBA) continuous infusion for 48 hours in moderate ARDS patients
Trial: 23018283
Drug: Clozapine suspension
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine suspension and Clozaril(®) tablets
Trial: 9928544
Drug: Estrogen/hormone replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen/hormone replacement therapy (ERT/HRT)
Trial: 8585289
Drug: Monovalent liposome‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent liposome‐adjuvanted vaccine
Trial: 8585289
Drug: Licensed trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed trivalent subvirion vaccine (reimmunization after 18 weeks)
Trial: 2816237
Drug: Thiopentone 6
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 6 mg/kg as a rapid intravenous bolus during CPB
Trial: 28969611
Drug: Web-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based intervention consisting of 10 modules tailored to treatment type, relationship status, and sexual orientation.
Trial: 18352915
Drug: Pamphlets +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamphlets + Lecture (P + L)
Trial: 17075906
Drug: Pharmacotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy combined with cognitive behavioral therapy (CBT)
Trial: 17075906
Drug: Pharmacological agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological agents
Trial: 24360599
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment
Trial: 11441210
Drug: Conventional aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional aphasia therapy
Trial: 1983347
Drug: sufotidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufotidine 600 mg nocte
Trial: 28715907
Drug: Immediate prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prolonged exposure treatment
Trial: 7799116
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and methylprednisolone
Trial: 1971708
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of propafenone every eight hours for five days
Trial: 1971708
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg of propafenone every eight hours for five days
Trial: 1971708
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of propafenone every eight hours for five days
Trial: 29200757
Drug: Topical amorolfine
RxNorm normalized name: amorolfine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical amorolfine lacquer monotherapy
Trial: 11176912
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg once daily for 7 days
Trial: 9589380
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (6 g, reduced to 3 g from day +30)
Trial: 8113551
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus antiplatelet therapy
Trial: 26345129
Drug: 1% flutamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% flutamide cream
Trial: 15637977
Drug: Re-dosing regimen
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-dosing regimen (2 doses at the start of brushing with 1 additional in-mouth dose during the last 30 seconds of brushing [2+1])
Trial: 15637977
Drug: Conventional regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimen (2 doses at the start of brushing only [2+0])
Trial: 26799502
Drug: Maternal stimulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal stimulant medication (MSM)
Trial: 23337174
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glucagon
Trial: 10021958
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml saline
Trial: 12444816
Drug: Hydroxyzine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (50 mg/day)
Trial: 27473633
Drug: Morning light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning light treatment (1 hour for 6 days)
Trial: 27473633
Drug: Evening light
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening light treatment (1 hour for 6 days)
Trial: 27473633
Drug: Both morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both morning and evening light treatments
Trial: 26090395
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids and Meriva (curcumin) at 2 g per day for 12 weeks
Trial: 26090395
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids alone for 12 weeks
Trial: 19540105
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Vitamin E (100 mg t.i.d.)
Trial: 16431252
Drug: Methylprednisolone alternated
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone alternated with a cytotoxic drug every other month for 6 months (group A)
Trial: 16431252
Drug: Synthetic adrenocorticotropic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic adrenocorticotropic hormone administered twice a week for 1 year (group B)
Trial: 11694408
Drug: rHuEpo and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo and G-CSF
Trial: 20304348
Drug: parecoxib 20
RxNorm normalized name: parecoxib 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parecoxib 20 mg
Trial: 17982319
Drug: parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: parecoxib 40 mg
Trial: 16336326
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (MVAC/MVEC)
Trial: 11600586
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg/d)
Trial: 3236318
Drug: Amiloride 10
RxNorm normalized name: amiloride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 10 mg once daily
Trial: 2550642
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg once daily
Trial: 27811556
Drug: Sertraline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (mean dosage 123.8 mg/d, range 50-200 mg/d)
Trial: 24533896
Drug: Fluoxetine (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (normal pH subgroup)
Trial: 24533896
Drug: Fluoxetine (abnormal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (abnormal pH subgroup)
Trial: 19155748
Drug: Melatonin (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (8.5 mg immediate release and 1.5 mg sustained release)
Trial: 17484223
Drug: Measles Vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles Vaccine (MV) as the most recent vaccine
Trial: 963493
Drug: Nimorazole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimorazole (300 mg twice daily for 7 days)
Trial: 963493
Drug: Metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (200 mg three times a day for 7 days)
Trial: 25491597
Drug: Eplerenone 100
RxNorm normalized name: eplerenone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 100 mg
Trial: 12094341
Drug: Gemcitabine/cisplatin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/cisplatin combination
Trial: 12975670
Drug: M-VAC combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-VAC combination chemotherapy